Study of Antibodies Expression with Specific Peptide Stimulation Specimens from gp350 / 220 (EBV) in Cell B

Bambang Pristiwanto, Muhaimin Rifa’i


Nasopharyngeal Carcinoma (NPC) is caused by Eipstein Barr Virus (EBV) which attack nasopharyngeal epithelium. EBV uses protein gp350/220 in the infection mechanism in nasopharyngeal epithelial surface receptor, CR2. The purpose of this study was to test the vaccine candidate at in vivo method. Mus musculus(Balb/C) mice were used as animal model. In this experiment mice pups in the age of 2 weeks were used. Injection using a specific peptide sequences from EBV showed higher expression of IgM (2.01%) compared to control (1.02%). Injection of this peptide to mice pups also increase the expression of IgM. After injection with this peptide, IgD also increase (75.74) compare to control (65.59%) without manipulation. In contrast, injection of this peptide decreases the expression of IgA antibodies (0.57%) significantly compare to control (1.93%).


Semeru volcano; attenuation; Q-factor and internal structure.

Full Text:



Korcum, A.F., E. Ozyar, and A. Eyhan(2006), Epstein Barr Virus Genes and Nasopharengeal Cancer. Turkish Journal of Center 36(3), 97-103.

Brennan, B. (2006) Nasopharyngeal Carcinoma. Review in Orphanet Journal in Rare Disease, Biomed Central.

Lee, A.W., W. Foo, O. Mang, W.M. Sze, R. Chappell, W.H. Lau, and W.M. Ko(2003), Changing epidemiology of nasopharyngeal carcinoma in Hongkong over a 20 year period (1980-1999): an encouraging reduction in both incidence and mortality. Int J Cancer 103(5), 680-685.

Pazdur, Mary P., and J.L. Jones (2007), Vaccines: an innovative approach to

treating cancer. Journal of Infusion Nursing 30(3), 173–178.

Sitompul, Loly Sabrina, Nashi Widodo, M. Sasmito D., and Didik Y.U. (2012), Epitope Mapping of gp350/220 Conserved Domain of Epstein Barr Virus to Develop Nasopharyngeal Carcinoma (NPC) Vaccine. Bioinformation 8(10),479-482.

Lowy, I., Leclercq L, and Theze J (1985), Regulation of IgM expression by adjuvant activated splenic suppressor T cells. Cell Immunol J 94(2), 609-613.

Murphy, K., P. Travers & M. Walport (2008), Janeway’s Immunobiology. Garland Science, Taylor & Francis Group, LLC, New York.

O’Hagan, D.T. (2000). Vaccine adjuvants. Humana Press, Inc. New Jersey, USA.



  • There are currently no refbacks.